SCHEMBL30220138

SCHEMBL30220138

CC(C)(C)OC(=O)Cn1ccc2ccc(Cl)cc2c1=O

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.45
USP2 O75604 1/20 0.45
LMNA P02545 1/20 0.45
KDM4E B2RXH2 3/20 0.44
DDR1 Q08345 1/20 0.43
MEN1 O00255 1/20 0.42
KMT2A Q03164 1/20 0.42
CYP3A4 P08684 1/20 0.41
CYP2C19 P33261 1/20 0.41
PSMB1 P20618 2/20 0.41
PSMB5 P28074 2/20 0.41
HDAC6 Q9UBN7 2/20 0.40
FPR2 P25090 1/20 0.40
GABRA1 P14867 1/20 0.39
GABRG2 P18507 1/20 0.39
GABRB3 P28472 1/20 0.39
GABRA5 P31644 1/20 0.39
KMO O15229 1/20 0.39
TNF P01375 2/20 0.37
VEGFA P15692 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15076008 0.82 KDM4E (0.63) ALDH1A1USP2LMNAKDM4EMEN1
SCHEMBL22404777 0.81 PSMB1 (0.47) ALDH1A1USP2LMNAKDM4EDDR1
SCHEMBL22390653 0.80 KMO (0.51) ALDH1A1USP2LMNAKDM4EDDR1
SCHEMBL31618416 0.78 KDM4E (0.44) ALDH1A1KDM4EHDAC6FPR2TNF
SCHEMBL87371 0.74 MDM2 (0.41) LMNAKDM4EDDR1GABRA1GABRG2
SCHEMBL31306259 0.73 TNF (0.51) ALDH1A1USP2LMNAKDM4EMEN1
SCHEMBL16293127 0.73 HDAC6 (0.40) ALDH1A1LMNAKDM4EKMT2AHDAC6
SCHEMBL31688961 0.72 KRAS (0.47) ALDH1A1KDM4EFPR2GABRA1GABRG2
SCHEMBL12480220 0.72 PTGDR2 (0.44) ALDH1A1KDM4EKMT2AGABRA1GABRG2
SCHEMBL15030294 0.72 KDM4E (0.42) ALDH1A1KDM4EKMT2AHDAC6FPR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3935042-B1 CASPASE INHIBITORS AND METHODS OF USE THEREOF NOBO MEDICINE INC (KR) 2024-08-28 EP disclosed
US-12071412-B2 Caspase inhibitors and methods of use thereof NOBO MEDICINE INC. (KR) 2024-08-27 US disclosed
US-20230250067-A1 CASPASE INHIBITORS AND METHODS OF USE THEREOF NOBO MEDICINE INC. (KR) 2023-08-10 US disclosed
US-11597703-B2 Caspase inhibitors and methods of use thereof HISTOGEN, INC. (US) 2023-03-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230250067-A1 CASPASE INHIBITORS AND METHODS OF USE THEREOF CASP1, CASP3, CASP7 ALDH1A1 2161/4885USP2 551/4885LMNA 93/4885
US-12071412-B2 Caspase inhibitors and methods of use thereof CASP1, CASP3, CASP7 ALDH1A1 2161/4885USP2 551/4885LMNA 93/4885
US-11597703-B2 Caspase inhibitors and methods of use thereof CASP1, CASP3, CASP7 ALDH1A1 2161/4885USP2 551/4885LMNA 93/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.